T. Gallenne

Abstract LB-261: Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2:HER3 heterodimer

P. Loo, T. Logtenberg, R. Roovers, 2015 .

Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis

Sridhar Ramaswamy, Ben S. Wittner, Fabien Reyal, 2013, Proceedings of the National Academy of Sciences.

The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death.

P. Cartron, F. Vallette, P. Juin, 2006, Cancer research.

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.

P. Gros, T. Logtenberg, D. Maussang, 2018, Cancer cell.

Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members

J. Hickman, P. Cartron, L. Oliver, 2009, The Journal of cell biology.

Bax Activation by Engagement with, Then Release from, the BH3 Binding Site of Bcl-xL

J. Hickman, P. Cartron, F. Vallette, 2010, Molecular and Cellular Biology.

Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer

Ben S. Wittner, B. Wittner, K. Ross, 2017, Oncotarget.

The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA.

Philippe Juin, P. Cartron, F. Vallette, 2004, Molecular cell.

Abstract 33: The binding mode of the bispecific anti-HER2xHER3 antibody MCLA-128 is responsible for its potent inhibition of HRG-driven tumorigenesis

P. Gros, T. Logtenberg, M. Throsby, 2017 .